Valiant Laborato Q1 FY27 Results (NSE: VALIANTLAB)
Signal: Margins at cyclical peak
The read
Q1FY27 marks a sharp margin inflection: consolidated EBITDA margin rose to 26.1% from 5.1% YoY and 5.2% in Q4FY26, while gross margin expanded 2,605bps as raw-material intensity fell 2,168bps; the key thesis question is whether this input-cost benefit persists, since the subsidiary drove most of the ₹2,110.30 lakh group PAT.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹115.29 Cr | 146.2% | +25.3% |
| EBIT | ₹27.26 Cr | 981.7% | |
| Net profit | ₹21.1 Cr | 1059.3% | |
| EPS | ₹3.89 | 826.2% | |
| EBIT margin | 26.1% |
P&L walk
Consolidated revenue rose to ₹11,528.51 lakh, +146.2% YoY and +25.3% QoQ, while gross margin expanded to 41.2% from 15.2% as raw-material intensity fell to 54.1% from 75.7%; EBITDA increased to ₹3,012.00 lakh and margin reached 26.1%, with PAT at ₹2,110.30 lakh despite higher finance cost and depreciation.
Segments
The company reports a single chemicals segment; the subsidiary is the main growth engine, contributing approximately ₹4,186.40 lakh of consolidated revenue and ₹1,162.42 lakh of consolidated PAT beyond the standalone result.
Key positives
- Consolidated revenue reached ₹11,528.51 lakh, +146.2% YoY and +25.3% QoQ, extending the recovery from ₹4,682.27 lakh in Q1FY26.
- Gross margin expanded to 41.2% from 15.2% YoY as raw-material cost fell to 54.1% of revenue from 75.7%.
- EBITDA margin expanded to 26.1% from 5.1% YoY; EBITDA grew +887.5% versus revenue growth of +146.2%, a +741.3pp growth gap, with margin expansion supported by lower raw-material intensity.
- PAT rose to ₹2,110.30 lakh from ₹182.09 lakh YoY, with other income of ₹86.03 lakh and no exceptional item, indicating the rebound was primarily operating.
Key concerns
- The 2,605bps consolidated gross-margin tailwind is the first major confirmation point after Q4FY26 gross-margin pressure; the filing does not disclose whether it reflects input deflation, pricing or mix and therefore persistence is unproven.
- Consolidated PAT growth of +1,059.3% lagged EPS growth of +826.2%, while paid-up capital increased from ₹4,345.00 lakh to ₹5,431.25 lakh, indicating dilution pressure on per-share economics.
- Finance cost increased +1,355.4% YoY to ₹106.65 lakh and depreciation increased +437.3% YoY to ₹286.11 lakh, despite the operating recovery.
Research and educational content only. Not investment advice.